WA1
AZN icon

Wimmer Associates 1’s AstraZeneca AZN Stock Holding History

Wimmer Associates 1’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-21,560
Closed -$1.47M – 109
2017
Q2 		$1.47M Sell
21,560
-257
-1% -$16.8K 1.35% 31
2017
Q1 		$1.36M Buy
+21,817
New +$1.27M 1.27% 31

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wimmer Associates 1's AZN Position: Q3 2017 in Review

Wimmer Associates 1 sold out of AstraZeneca (AZN) in Q3 2017, closing a stake of 21,560 shares — an estimated $1.47M sold.

Wimmer Associates 1 first reported a position in AZN in Q1 2017 and held it in 2 quarters. The position peaked at $1.47M in Q2 2017. 455 funds tracked by Wall St. Rank hold AZN as of Q3 2017.

  • Wimmer Associates 1 reported no remaining AstraZeneca position as of Q3 2017 after selling out during the quarter.
  • Wimmer Associates 1 sold 21,560 AstraZeneca shares in Q3 2017, an estimated $1.47M.
  • Wimmer Associates 1 first reported a position in AstraZeneca in Q1 2017 and held it in 2 quarters.
  • Wimmer Associates 1's AstraZeneca position peaked at $1.47M in Q2 2017.
  • 455 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2017.

Based on Wimmer Associates 1's 13F filing for Q3 2017, filed 14 Nov 2017.